UK injection moulder Boddingtons looks back on a positive end-of-year review of its services and capabilities.
Boddingtons
Boddingtons CEO Andy Tibbs, (Left), Boddingtons Business Development Managers, Chris Philpott (Middle) & Tony Ayley (Right).
Andy Tibbs, CEO, said: “We used the post-pandemic period to grow and consolidate our investments, technical capabilities, and services; both for Class 7 cleanroom and non-cleanroom production. That was the theme of 2022 and now we believe we’re in great shape for whatever 2023 might throw at us.”
Boddingtons is currently completing processing the orders and enquiries received on its stand at Düsseldorf’s MEDICA/COMPAMED exhibition from November. A number of new developmental healthcare and medical projects will be in play at the company through 2023 in preparation for production in 2024. New marketing initiatives also see Boddingtons adding Pharmapack in Paris to its 2023 roster of exhibiting presences.
Chris Philpott, business development manager said: “We are succeeding in generating new spin-off sectors from our core competences in healthcare, medical and cleanroom-based production. The pharmaceutical market is one of these. We walked the Paris show this year, and such was the footfall and energy there that we decided to exhibit in 2023.”
Q1 2023 should also see the Boddingtons business announce further new developments in its standards work. From concept design, tooling, validation, CE marking to medical device registrations, Boddingtons offers its customers a fully managed programme; helping them with new product introductions and the increase of market share.
Boddingtons operates a facility in South East England for the production of injection-moulded components, medical devices and assemblies. All manufacturing is included within the scope of ISO 13485 and MDSAP accreditations. Boddingtons has won the Plastics Industry Awards (PIA) a record-breaking four times for its design-for-manufacture expertise and was a finalist in three PIA categories in 2022.
